CMS Open Payments · Program Year 2024
Pinnacle Biologics, Inc
Pinnacle Biologics, Inc reported $75,395.74 across General Payments, Research, and Ownership to 342 physicians and teaching hospitals across 343 transactions.
- $75.4K Below-median payer
- All-tracks total
- 343 Above-median volume
- Transactions
- 342 Above-median reach
- Recipients
- −$85.2K
- General Payments vs PY2023
Pinnacle Biologics, Inc reported $75,395.74 across all CMS Open Payments tracks (General + Research + Ownership) to 342 physicians and teaching hospitals in Program Year 2024 - ranking #1255 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $70,645.74, averaging $220.46 per recipient.
How Pinnacle Biologics, Inc's $75.4K all-tracks total breaks down
Pinnacle Biologics, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
11/100
Transaction volume
F
12/100
Physician reach
F
13/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pinnacle-biologics-inc Pinnacle Biologics, Inc
$75.4K · #1255/1,925 · 0.0% industry · PY2024
- TOT $75.4K
- RANK #1255
- SHARE 0.0%
- TXN 343
- RCP 342
- CAT 4
- GEN $70.6K
- ΔGEN −$85.2K
- TOP1 10.2%
- PY 2024
Volume peers
Nearest volume peer: Medexus Pharma, Inc. ($75.6K)
Pinnacle Biologics, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pinnacle Biologics, Inc's CMS-reported General Payments decreased by $85.2K (−54.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PINNACLE BIOLOGICS, INCPY2023: PINNACLE BIOLOGICS, INCPY2024: Pinnacle Biologics, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $155,854.50
- PY2024
- $70,645.74
What the Data Shows for Pinnacle Biologics, Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Pinnacle Biologics, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Compensation for Services Other Than Consulting" leads the 4-category general-payment breakdown below at $32.6K (46.2% of General Payments, 13 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Pinnacle Biologics, Inc made 4 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $32.6K, 46.2% of General Payments.
Pinnacle Biologics, Inc reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (46.2%), Food and Beverage (31.2%), and Travel and Lodging (15.3%). The remaining 1 category make up 7.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Pinnacle Biologics, Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $32.6K | 13 | 46.2% |
| Food and Beverage | $22.0K | 299 | 31.2% |
| Travel and Lodging | $10.8K | 29 | 15.3% |
| Consulting Fee | $5.2K | 1 | 7.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,026.38 (39.7%) of $70,645.74 in this company's General Payments records across 241 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pinnacle Biologics, Inc
The five named recipients with the highest reported General Payments from this company
- 1
George Cheng
$7,216.57 across 6 reported transactions
- 2
Jonathan Kurman
$7,000.00 across 3 reported transactions
- 3
Kamran Ayub
$5,123.78 across 6 reported transactions
- 4
Amit Tandon
$4,616.03 across 2 reported transactions
- 5
Venkatesh Lakshminarayanan
$4,070.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pinnacle Biologics, Inc's spend rank (#1255 of 1,925, bottom 35% by spend) and concentration rank (#1,334 of 1,838, bottom 27% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Neuronetics, Inc. : $1.1M total payments, HHI 449
- OrthoPediatrics Corp. : $2.7M total payments, HHI 449
- Rhythm Pharmaceuticals, Inc. : $177.0K total payments, HHI 449
- Linvatec Corporation : $5.3M total payments, HHI 448
- Midsouth Orthopedics Inc. : $10.7K total payments, HHI 447
- Acclarent, Inc : $232.0K total payments, HHI 447
- Pinnacle Biologics, Inc (this company) : $70.6K total payments, HHI 445
- Gentleman Orthopedic Solutions : $20.0K total payments, HHI 445
- Blue Earth Diagnostics Limited : $324.1K total payments, HHI 444
- Trilliant Surgical LLC. : $844.6K total payments, HHI 443
- Innovasis Inc : $1.1M total payments, HHI 441
- Avadel CNS Pharmaceuticals, LLC : $1.5M total payments, HHI 441
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pinnacle Biologics, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pinnacle Biologics, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pinnacle Biologics, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Evolution Surgical, Inc
Clinician's Choice Dental Products Inc.
Aspira Women's Health Inc
Advanced Sterilization Products Services Inc.
Ascend Therapeutics US, LLC
Put this to use
Pinnacle Biologics, Inc ranks #1255 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Pinnacle Biologics, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.